THE US Food and Drug Administration has approved a new treatment for patients diagnosed with moderate to severe central sleep apnoea.
The Remed System is an implantable device that stimulates a chest nerve that is responsible for sending signals to the diaphragm to stimulate breathing.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Oct 17
